- Report
- March 2024
- 193 Pages
Global
From €3237EUR$3,374USD£2,788GBP
€3597EUR$3,749USD£3,098GBP
- Report
- March 2024
- 199 Pages
Global
From €3237EUR$3,374USD£2,788GBP
€3597EUR$3,749USD£3,098GBP
- Report
- February 2024
- 250 Pages
Global
From €4797EUR$5,000USD£4,132GBP
- Report
- February 2024
- 175 Pages
Global
From €4797EUR$5,000USD£4,132GBP
- Report
- February 2024
- 250 Pages
Global
From €4797EUR$5,000USD£4,132GBP
- Report
- October 2023
- 189 Pages
Global
From €4701EUR$4,900USD£4,049GBP
- Report
- October 2023
- 180 Pages
Global
From €4701EUR$4,900USD£4,049GBP
- Report
- August 2023
- 295 Pages
Global
From €9115EUR$9,500USD£7,851GBP
- Report
- January 2024
- 113 Pages
Global
From €4318EUR$4,500USD£3,719GBP
- Report
- April 2024
- 318 Pages
From €5227EUR$5,639USD£4,350GBP
- Report
- October 2022
- 270 Pages
Global
From €3598EUR$3,750USD£3,099GBP
- Report
- December 2022
- 150 Pages
Global
From €5709EUR$5,950USD£4,917GBP
- Report
- September 2022
- 232 Pages
Global
From €3358EUR$3,500USD£2,892GBP
- Report
- September 2022
- 282 Pages
Global
From €9115EUR$9,500USD£7,851GBP
- Report
- February 2022
- 210 Pages
Global
From €7196EUR$7,500USD£6,198GBP
- Report
- January 2022
- 90 Pages
Global
From €1919EUR$2,000USD£1,653GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2639EUR$2,750USD£2,273GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2639EUR$2,750USD£2,273GBP
- Report
- February 2022
- 228 Pages
Global
From €7196EUR$7,500USD£6,198GBP
- Report
- January 2022
- 200 Pages
Global
From €7196EUR$7,500USD£6,198GBP
Remicade is a biologic drug used to treat immune disorders such as Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. It is a monoclonal antibody that works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Remicade is administered intravenously and is usually given in a series of three infusions over a period of several weeks.
Remicade is a major player in the immune disorders drugs market, with a wide range of indications and a long track record of safety and efficacy. It is one of the most widely prescribed biologic drugs in the world, and is used by millions of patients.
Companies in the Remicade market include Johnson & Johnson, Merck, Pfizer, AbbVie, and Amgen. Show Less Read more